Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes

Canadian Journal of Diabetes

Volumn 29, Issue 2, 2005, Pages 95-101

  Leblond, Julie ^a   Pilon, Danielle ^a   Beaudette, Christian Pierre ^a   Maheux, Pierre ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

Antihyperglycemic agents; Database; Drug persistence; Pharmacoepidemiology; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; LOOP DIURETIC AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL SPECIALIST; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; REIMBURSEMENT; SCORING SYSTEM; SEX DIFFERENCE;

EID: 33646713414     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Goldstein BJ. Differentiating members of the thiazolidinedione class: a focus on efficacy. Diabetes Metab Res Rev. 2002;18 (suppl 2):S16-S22.
2. Pittas AG, Greenberg AS. Thiazolidinediones in the treatment of type 2 diabetes. Expert Opin Pharmacother. 2002;3:529-540.
3. Canadian Pharmacists Association. Compendium of Pharmaceuticals and Specialties: The Canadian Drug Reference for Health Professionals. Ottawa, ON: Canadian Pharmacists Association; 2003.
4. Catalan VS, Couture JA, LeLorier J. Predictors of persistence of use of the novel antidiabetic agent acarbose. Arch Intern Med. 2001;161:1106-1112.
5. Boccuzzi SJ, Wogen J, Fox J, et al. Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes Care. 2001;24:1411-1415.
6. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin Ther. 2001;23:1311-1320.
7. US Food and Drug Administration. US Food and Drug Administration web site. Modification to the WARNINGS, PRECAUTIONS, and ADVERSE REACTIONS sections of the labels for ACTOS and AVANDIA. Available at: http://www.fda.gov/medwatch/ safety/2002/summary-actos-avandia.pdf. Accessed April 29, 2005.
8. Health Canada. Health Canada Online website. Important safety reminder for patients taking oral diabetes drugs of the glitazone class, Avandia® and Actos®. Available at: http://www.hc-sc. gc.ca/english/protection/warnings/ 2001/2001_132e.htm. Accessed April 29, 2005.
9. Wooltorton E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. CMAJ. 2002;166:219.
10. Régie de l'assurance maladie du Québec. Prescription drug insurance program 2003 web site. Available at: http://www.ramq. gouv.qc.ca/en/statistiques/statistiques/assurancemedicaments 2003.shtml. Accessed April 29, 2005.
11. Grégoire J-P, Moisan J, Chabot I, et al. Appropriateness of omeprazole prescribing in Quebec's senior population. Can J Gastroenterol. 2000;14:676-680.
12. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Québec. J Clin Epidemiol. 1995;48:999-1009.
13. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45:197-203.
14. Kleinbaum DG. The Cox proportional hazards model and its characteristics. In: Dietz K, Gail M, Krickeberg K, eds. Survival Analysis: A Self-Learning Text. New York, NY: Springer-Verlag; 1996:83-128.
15. Régie de l'assurance maladie du Québec. Liste de médicaments assurés web site. Available at: http://www.ramq.gouv. qc.ca/fr/professionnels/listmed/lm_tdmf.shtml. Accessed April 29, 2005.
16. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc. 2003;78:1088-1091.
17. Tang WH, Francis GS, Hoogwerf BJ, et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol. 2003;41:1394-1398.
18. Niemeyer NV, Janney EM. Thiazolidinedione-induced edema. Pharmacotherapy. 2002;22:924-929.
19. Streeten DH. Idiopathic edema. Pathogenesis, clinical features, and treatment. Endocrinol Metab Clin North Am. 1995;24:531-547.
20. MacGregor GA, Markandu ND, Roulston JE, et al. Is "idiopathic" edema idiopathic? Lancet. 1979;1:397-400.
21. Pilon D, Castilloux A-M, LeLorier J. Estrogen replacement therapy: determinants of persistence with treatment. Obstet Gynecol. 2001;97:97-100.
22. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care. 2004;42:102-109.